Pune Expansion Marks Deeper India Ties

Boston Scientific's decision to lease a large office space in Pune for its Global Capability Centre (GCC) shows India's growing importance for high-value corporate functions, not just cost savings. The 130,682 sq ft facility in Wakad signals a stronger commitment to using India's technical talent and innovation, even as the company deals with stock market changes and legal challenges.

New Pune Facility Details

Boston Scientific Technology and Engineering Services has signed a long-term lease for over 130,000 square feet in Tower D at Eon West LP II in Wakad, Pune. The lease runs for nearly 9.5 years with a monthly rent of about ₹86.58 lakh (₹66.25 per sq ft). The company also has an option to take an extra floor by March 2027, showing plans for continued growth. This GCC facility builds on Boston Scientific's existing R&D centers in India, which opened in Gurgaon in 2014 and Pune in 2016, with another Pune R&D site launching in 2022. The GCC is expected to handle wider operations, including technology, engineering, and global support, using Pune's status as an engineering and IT hub.

India's Office Market: GCC Growth Fuels Demand

The lease fits into a strong trend in India's commercial real estate market, where Global Capability Centres (GCCs) are leading office space absorption. In Q1 2026, GCCs leased 9.1 million sq ft nationwide, making up a large part of the total 20.7 million sq ft leased. Pune, with a vacancy rate of 11.23% in Q1 2025, is India's second-hottest office market after Bengaluru, attracting global firms looking for good space and skilled workers. While areas like Kharadi see higher rents (₹98.84/sq ft in Q1 2025), Wakad offers a more affordable ₹66.25/sq ft, suitable for large operations. Pune's office supply is expected to grow 3-4% in FY2026, confirming its importance for corporate growth.

Boston Scientific Faces Stock Woes and Lawsuits

Boston Scientific's stock performance contrasts sharply with its expansion efforts in India. The company's shares have dropped about 42.1% since January 1, 2026, trading close to their 52-week low of $54.98. This decline comes as the company faces several securities class-action lawsuits alleging misleading statements about its electrophysiology business. The stock also fell 12% in the past week. Company management has lowered its full-year 2026 forecast, pointing to challenges with procedural volumes, increased competition in areas like electrophysiology, and integration difficulties from recent acquisitions. Boston Scientific also has a history of paying large sums for patent infringements, including settlements with Johnson & Johnson, Nevro, and TissueGen. These issues raise concerns about the company's operational performance and financial health, despite its growth signals in India.

Analyst Views and Company Outlook

Despite these challenges, analysts generally remain optimistic, giving Boston Scientific a 'Moderate Buy' consensus rating and an average price target of $93.91, suggesting potential for significant upside. This positive view is supported by the company's market value of around $82.18 billion and its steady investment in research and development. Boston Scientific's Q1 2026 net sales grew 11.6% year-over-year. The Pune GCC expansion aligns with a wider trend of India evolving into a center for innovation, with GCCs focusing more on AI, engineering, and product development, not just administrative tasks. However, the combination of stock price swings, pending legal cases, and a lowered forecast means the company must overcome substantial operational difficulties and manage its legal issues to achieve its growth targets. The Pune lease is a clear investment in future capacity, but its success hinges on the company improving its financial performance and resolving its legal disputes.